Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GL0034 in Adults With Type 2 Diabetes Mellitus
2024-513279-41-00Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Jul 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing UTREGLUTIDE (GL0034) once weekly with Placebo once weekly (2 arms). Primary endpoints: Incidence and severity of gastrointestinal adverse events and Frequency of gastrointestinal adverse events per participant. Started Jul 2024; status: completed.
02
Drugs
utreglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-513279-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513279-41-00.